Vera Therapeutics Stock News

BRISBANE, Calif., Jan. 04, 2022 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA), a clinical-stage biotechnology company focused on developing and commercializing transformative treatments f

Vera Therapeutics (NASDAQ:VERA) was downgraded by Zacks Investment Research from a buy rating to a hold rating in a report issued on Friday, Zacks.com reports. According to Zacks, Vera Therapeutics Inc. is a clinical-stage biotechnology company. It is focused on developing and commercializing transformative treatments for patients with serious immunological diseases. Vera Therapeutics Inc. is []

Ongoing Phase 2 clinical trial for MAU868 in kidney transplant patients; potential first-in-class

Vera Therapeutics (VERA) has been struggling lately, but the selling pressure may be coming to an end soon.

Pharmaceutical industry leader brings more than 30 years of quality, regulatory and manufacturing experience Pharmaceutical industry leader brings more than 30 years of quality, regulatory and manufacturing experience

Vera Therapeutics, Inc. (NASDAQ:VERA) shares fell 10.6% during mid-day trading on Wednesday . The company traded as low as $25.84 and last traded at $25.84. 1,131 shares were traded during mid-day trading, a decline of 98% from the average session volume of 54,135 shares. The stock had previously closed at $28.89. Separately, Zacks Investment Research []

Vera Therapeutics, Inc. (NASDAQ:VERA) Stock analysts at Jefferies Financial Group raised their FY2021 earnings per share estimates for Vera Therapeutics in a research note issued on Monday, December 6th. Jefferies Financial Group analyst M. Raycroft now anticipates that the company will post earnings per share of ($2.14) for the year, up from their previous []

Vera Therapeutics, Inc. (NASDAQ:VERA) shot up 11.2% during mid-day trading on Monday . The stock traded as high as $32.09 and last traded at $31.19. 1,895 shares changed hands during mid-day trading, a decline of 96% from the average session volume of 46,921 shares. The stock had previously closed at $28.05. Separately, Zacks Investment Research […]

Vera Therapeutics, Inc. (NASDAQ:VERA)s share price reached a new 52-week high on Wednesday . The stock traded as high as $37.08 and last traded at $35.80, with a volume of 297 shares changing hands. The stock had previously closed at $35.80. Separately, Zacks Investment Research raised shares of Vera Therapeutics from a sell rating to []

Vera Therapeutics, Inc. (NASDAQ:VERA)s stock price dropped 7.4% during trading on Thursday . The company traded as low as $29.35 and last traded at $30.81. Approximately 2,118 shares traded hands during mid-day trading, a decline of 96% from the average daily volume of 54,494 shares. The stock had previously closed at $33.28. Separately, Zacks Investment []

Vera Therapeutics, Inc. (NASDAQ:VERA) shares gapped up prior to trading on Tuesday . The stock had previously closed at $26.89, but opened at $28.72. Vera Therapeutics shares last traded at $29.94, with a volume of 278 shares changing hands. Separately, Zacks Investment Research raised Vera Therapeutics from a sell rating to a hold rating in []

Vera Therapeutics (NASDAQ:VERA) was upgraded by Zacks Investment Research from a sell rating to a hold rating in a note issued to investors on Wednesday, Zacks.com reports. According to Zacks, Vera Therapeutics Inc. is a clinical-stage biotechnology company. It is focused on developing and commercializing transformative treatments for patients with serious immunological diseases. Vera Therapeutics []

Vera Therapeutics, Inc. (NASDAQ:VERA) saw a large growth in short interest during the month of October. As of October 29th, there was short interest totalling 185,100 shares, a growth of 43.8% from the October 14th total of 128,700 shares. Based on an average daily volume of 71,300 shares, the days-to-cover ratio is currently 2.6 days. []